We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > LentiGlobin

News List

bluebird bio’s sickle cell gene therapy granted MHRA ‘innovation passport’ pharmatimes
July 01, 2021
bluebird bio’s gene therapy for sickle cell disease LentiGlobin has been granted an ‘innovation passport’ from the UK Medicines and Healthcare products Regulatory Agency (MHRA).
bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology firstwordpharma
December 05, 2018
SCD is a serious, progressively debilitating and life-threatening genetic disease. SCD results from production of abnormal sickle hemoglobin (HbS), which leads to sickled red blood cells (RBCs) and hemolysis.
EU regulators to review bluebird’s gene therapy LentiGlobin pharmatimes
October 11, 2018
The European Medicines Agency will undertake an accelerated review of bluebird bio’s LentiGlobin, a gene therapy for the treatment of transfusion-dependent beta-thalassemia.